The Perils of Over-The-Counter Antibiotics:
FDA Regulatory Frameworks, Antimicrobial Resistance,
and the Imperative of Antimicrobial Stewardship

1. Introduction

The regulatory distinction between over-the-counter (OTC) and prescription-only (Rx) medications in the United States represents one of the most consequential regulatory frameworks in modern public health. For no drug class is this distinction more pharmacologically and epidemiologically significant than for antibiotics. The antibiotic landscape in the United States is governed by a principle that has, thus far, maintained a critical public health safeguard: that systemic antibiotic agents — those absorbed into the bloodstream and distributed throughout the body — require a valid prescription from a licensed healthcare provider. This requirement is not bureaucratic formality; it reflects decades of hard-won understanding of antibiotic pharmacology, the biology of antimicrobial resistance (AMR), and the inescapable epidemiology of antibiotic-driven ecological disruption.

Yet the erosion of this principle — through unregulated online pharmacies, cross-border internet medication purchases, and the informal sharing of antibiotic prescriptions — constitutes a growing and underappreciated threat to US public health that demands rigorous academic scrutiny. The World Health Organization (WHO) has designated antimicrobial resistance as one of the ten greatest threats to global health, while the CDC's 2023 AMR Threat Report estimated that more than 2.8 million antibiotic-resistant infections and over 35,000 deaths occur annually in the United States alone. [1] Understanding why the prescription requirement exists — and what happens when it is bypassed — is not merely an academic exercise; it is a matter of immediate and escalating public health urgency.

This article provides an evidence-based, scholarly examination of the current US regulatory framework for antibiotic classification, the molecular and epidemiological consequences of unregulated systemic antibiotic use, and the essential role of antimicrobial stewardship programs in preserving the clinical utility of the antimicrobial armamentarium for future generations of Americans.

2. The FDA Regulatory Framework: OTC vs. Prescription Antibiotics in the United States

In the United States, the classification of a drug as OTC or prescription-only is governed by the Federal Food, Drug, and Cosmetic Act (FD&C Act, 21 U.S.C. § 353(b)), which specifies that a drug must be dispensed only upon prescription if: (i) it is not safe for use without the supervision of a licensed practitioner due to its toxicity or potential for harmful effect; or (ii) its method of administration, or the collateral measures necessary for its use, require the supervision of a practitioner; or (iii) it is habit-forming. [2] All three criteria are highly relevant to systemic antibiotics.

2.1 FDA-Approved Topical OTC Antibiotic Products

The United States does permit a limited category of topically applied antibiotic agents to be sold OTC for first aid use in wound care. The FDA OTC Drug Monograph system has determined that certain active ingredients — most notably bacitracin, polymyxin B sulfate, and neomycin sulfate (and their combination products) — are generally recognized as safe and effective (GRASE) for topical application to minor cuts, scrapes, and burns when used as directed.[3]

The pharmacological basis for permitting these agents OTC is their minimal systemic absorption when applied to intact or minor-injury skin. Bacitracin, a polypeptide antibiotic that inhibits bacterial cell wall synthesis by blocking the dephosphorylation of the C55-isoprenyl pyrophosphate lipid carrier required for peptidoglycan precursor transport, is essentially non-absorbable through intact skin at concentrations used in topical preparations, resulting in negligible systemic exposure. Polymyxin B similarly exerts its action (disruption of bacterial outer membrane phospholipid integrity) only locally. The risk of driving systemic antimicrobial resistance through topical application of these agents is substantially lower than through systemic dosing — though not entirely absent, as discussed in Section 3.

2.2 The Prescription Status of Systemic Antibiotics: Regulatory Rationale

All systemic antibiotic agents approved by the FDA for use in the United States — including the agents discussed throughout this Institute's monograph library (amoxicillin, doxycycline, azithromycin, trimethoprim-sulfamethoxazole, ciprofloxacin) — are classified as prescription-only (Rx) medications. This classification is not incidental. The FDA's determination that these drugs require professional supervision rests on multiple, independently sufficient grounds:

• ▸Diagnostic complexity: Appropriate antibiotic selection requires an accurate diagnosis, which typically demands physical examination, laboratory culture and susceptibility testing, and clinical judgment that cannot be replicated by patient self-assessment.
• ▸Spectrum-matching: Each antibiotic class has a defined spectrum; selecting an agent with insufficient coverage, or unnecessarily broad coverage, has direct pharmacological and ecological consequences.
• ▸Resistance induction risk: Sub-therapeutic dosing, inappropriate drug selection, and incomplete courses all contribute to resistance selection pressure.
• ▸Drug interaction and contraindication management: Multiple clinically significant drug interactions (e.g., fluoroquinolones with antacids; macrolides with CYP3A4 substrates) and absolute contraindications require professional risk assessment.
• ▸Adverse effect monitoring: Serious adverse effects (anaphylaxis, SJS/TEN, tendinopathy, nephrotoxicity, C. difficile colitis) require clinical recognition and management capacity unavailable in self-treatment contexts.

This multi-dimensional justification for prescription status is reinforced by international evidence: countries with more permissive OTC antibiotic availability — including several Latin American and Asian nations where certain systemic antibiotics are informally available without prescription — consistently demonstrate significantly higher rates of antimicrobial resistance in community-acquired pathogens compared to nations with stringent prescription requirements. [4]

3. The Mechanism of Resistance: How Unregulated Antibiotic Use Accelerates AMR

Antimicrobial resistance is not a random or unpredictable biological phenomenon; it is the direct, mechanistically predictable consequence of antibiotic use. The fundamental Darwinian principle is straightforward: antibiotics create a powerful selective pressure that favors the survival and proliferation of bacterial variants capable of withstanding drug concentrations to which susceptible members of the same population are killed or inhibited. Every course of antibiotic therapy — appropriate or inappropriate — contributes to this selective ecology.

3.1 Mutation-Selection and Resistance Amplification

Bacterial populations are genetically heterogeneous. Even in the absence of antibiotic exposure, spontaneous mutations in drug target genes (e.g., DNA gyrase in response to fluoroquinolones, PBPs in response to beta-lactams) occur at a background rate of approximately 10⁻⁸ to 10⁻¹⁰ per base pair per replication. In a large bacterial population — a single gram of intestinal content may contain 10⁸ to 10¹¹ bacterial cells — pre-resistant mutants exist before antibiotic exposure begins. [5] Antibiotic administration eliminates susceptible organisms while providing a growth advantage to these pre-existing resistant variants, which replicate to dominate the post-treatment population. This phenomenon is termed resistance amplification.

Critically, unregulated self-treatment scenarios dramatically worsen this problem through two principal mechanisms: subtherapeutic dosing and premature treatment cessation. Subtherapeutic dosing — arising from inadequate dose selection, incorrect duration, or poor compliance — creates precisely the pharmacodynamic conditions most favorable for resistance selection: concentrations sufficient to exert selective pressure against susceptible organisms but insufficient to reliably kill or fully suppress the growth of organisms with moderately elevated MICs. This "mutant selection window" between the MIC of susceptible organisms and the MIC of resistant mutants is widened by suboptimal pharmacokinetic parameters, amplifying resistance selection. [6]

3.2 Horizontal Gene Transfer: Resistance as a Communicable Trait

What distinguishes antimicrobial resistance from most other drug toxicity problems is its fundamentally transmissible and communicable nature. Antibiotic resistance determinants — resistance genes — can be transferred between bacteria via horizontal gene transfer (HGT) mechanisms, including conjugation (direct cell-to-cell transfer via pili), transformation (uptake of free DNA from the environment), and transduction (bacteriophage-mediated gene transfer). This means that resistance selected by antibiotic use in one individual patient can be passed to bacteria infecting entirely different individuals, or even to different bacterial species, rendering AMR a true public health epidemic rather than a purely individual pharmacological risk.

The plasmid-borne nature of many critically important resistance determinants — including extended-spectrum beta-lactamases (ESBLs), carbapenemases (e.g., KPC, NDM), and plasmid-mediated quinolone resistance (PMQR) genes — enables the rapid dissemination of high-level, multidrug resistance across entire microbial communities within healthcare facilities, nursing homes, and through community-associated transmission chains. The intestinal microbiome, with its enormous bacterial density, serves as a highly efficient reservoir and exchange hub for mobile resistance elements. [7]

3.3 Collateral Selection: The Bystander Effect of Antibiotic Use

Perhaps the most underappreciated aspect of antibiotic resistance ecology is collateral selection — the impact of antibiotic use on the resistance profiles of bacterial species beyond the target pathogen. When a patient takes a systemic antibiotic (e.g., azithromycin for suspected respiratory infection), the antibiotic does not selectively impact the presumed target pathogen; it subjects the entire intestinal and respiratory microbiome — representing hundreds of bacterial species — to selective pressure. This results in the simultaneous selection of resistance determinants in commensal bacteria that may subsequently serve as resistance gene donors to pathogenic organisms. Studies in human volunteers demonstrate measurable, long-lasting shifts in gut microbiome composition and resistome composition following even single short courses of commonly prescribed antibiotics. [8]

4. The Self-Diagnosis Problem: Viral vs. Bacterial Infections

A fundamental prerequisite for rational antibiotic use is accurate diagnosis. Antibiotics are pharmacologically active only against bacterial pathogens — they have no mechanism of action against viruses, fungi (with the narrow exception of certain agents active against fungal sterol synthesis, which are distinct drug classes), parasites, or autoimmune inflammatory conditions. Yet the failure of laypersons to distinguish viral from bacterial etiologies of common symptomatic illnesses represents one of the most pervasive drivers of inappropriate antibiotic use in the United States.

The common cold, seasonal influenza, the vast majority of acute upper respiratory tract infections, most cases of acute bronchitis, and most cases of acute pharyngitis in adults are caused by viruses — primarily rhinoviruses, coronaviruses, adenoviruses, influenza A and B viruses, and respiratory syncytial virus (RSV) — for which antibiotics are completely ineffective and offer no benefit to the patient. [9] The CDC estimates that approximately 30% of antibiotic prescriptions written in physician offices, emergency departments, and urgent care centers in the United States are unnecessary — principally for viral respiratory conditions. [1]

4.1 The Clinical Mimicry Problem

The diagnostic challenge is compounded by the symptom overlap between viral and bacterial infections. Streptococcal pharyngitis (bacterial), caused by Streptococcus pyogenes, can present with features clinically indistinguishable from viral pharyngitis — including sore throat, fever, tonsillar exudates, and cervical lymphadenopathy. Distinguishing these etiologies reliably requires either a rapid antigen detection test (RADT) for Group A Streptococcus, or a throat culture — neither of which is feasible in a self-treatment scenario. Similarly, community-acquired pneumonia caused by bacterial pathogens (Streptococcus pneumoniae, Haemophilus influenzae) may initially resemble viral pneumonitis in symptom presentation, and correct diagnosis requires chest radiography, leukocyte differential analysis, and C-reactive protein or procalcitonin measurement.

The consequence of antibiotic administration for viral illness is not merely pharmacological futility — the administration of antibiotics to a patient with a viral infection does not provide symptomatic benefit, does not shorten the duration of illness, and does not prevent secondary bacterial complications in the general population. [10] The actual consequences are pharmacologically adverse: the patient's microbiome is disrupted, resistance is selected in commensal flora, the patient is exposed to adverse effects (including Clostridioides difficile colitis risk), and resistance genes are propagated in the environment through fecal excretion.

5. Microbiome Dysbiosis: The Collateral Damage of Antibiotic Exposure

The human gastrointestinal microbiome represents an extraordinarily complex ecological community of approximately 10¹³ to 10¹⁴ microbial cells — a number roughly equivalent to or exceeding the total number of human somatic cells in the body — comprising over 1,000 distinct bacterial species in healthy adults. This community performs essential physiological functions including competitive exclusion of pathogens (colonization resistance), synthesis of short-chain fatty acids critical for colonocyte energy metabolism, regulation of intestinal immune responses, production of essential vitamins (K, B12, biotin), and modulation of the gut-brain axis. [11]

The term microbiome dysbiosis refers to a disruption of the normal composition, diversity, and functional ecology of the microbiome. Systemic antibiotic administration represents one of the most potent environmental perturbations to the human microbiome, with measurable effects on microbial diversity occurring within hours to days of antibiotic initiation. Studies using metagenomic sequencing have documented that even single short courses of broad-spectrum antibiotics (e.g., amoxicillin-clavulanate, ciprofloxacin, or clindamycin) can cause profound reductions in microbiome alpha-diversity (species richness within a sample) that persist for months to years post-treatment. [12]

5.1 Clostridioides difficile Infection: The Most Immediate Dysbiosis Risk

The most immediate, clinically significant consequence of antibiotic-induced dysbiosis is Clostridioides difficile (formerly Clostridium difficile) infection (CDI). C. difficile, a Gram-positive, spore-forming anaerobe, is present in low abundance in the intestinal microbiome of approximately 3–5% of healthy adults. In the dysbiotic environment created by antibiotic disruption of colonization resistance, C. difficile spores — which are intrinsically resistant to virtually all commonly used antibiotic classes — can germinate, proliferate, and produce toxins A (enterotoxin) and B (cytotoxin) that cause pseudomembranous colitis, manifesting as profuse watery diarrhea, abdominal cramping, and, in severe cases, toxic megacolon and sepsis. [13]

The CDC designates C. difficile as an "Urgent Threat" — the highest risk category in its AMR Threat Report. Approximately 500,000 Americans develop CDI annually, with approximately 15,000 to 30,000 deaths attributable to the condition each year. Critically, virtually all cases of CDI are preceded by antibiotic exposure — reinforcing that inappropriate, self-directed antibiotic use carries tangible, sometimes fatal, consequences that are entirely preventable through prescription oversight. [1]

5.2 Long-Term Microbiome Consequences and Emerging Research

Beyond immediate CDI risk, emerging research implicates antibiotic-induced dysbiosis in a broad spectrum of long-term health outcomes including increased susceptibility to metabolic disorders (obesity, type 2 diabetes), inflammatory bowel disease (IBD), allergic diseases (atopy, asthma), and neuropsychiatric conditions mediated through the gut-brain axis. While causality for most of these associations remains under active investigation, the mechanistic plausibility is well-established, and the precautionary principle argues strongly against unnecessary antibiotic exposure — particularly in vulnerable populations including infants, the elderly, and the immunocompromised. Early childhood antibiotic exposure, in particular, has been associated in multiple longitudinal cohort studies with altered immune maturation and increased rates of atopic disease, though confounding variables require continued methodological scrutiny. [14]

6. Antimicrobial Stewardship: The Evidence-Based Public Health Response

Antimicrobial stewardship programs (ASPs) represent the structured, evidence-based organizational response to the dual imperatives of optimizing antibiotic therapy for individual patients while preserving the long-term efficacy of the antimicrobial armamentarium for populations. The Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), and the Pediatric Infectious Diseases Society (PIDS) have jointly published foundational guidelines establishing the core elements of effective ASPs. [15]

6.1 Core ASP Interventions

The evidence base for ASP efficacy in the inpatient hospital setting is robust: systematic reviews and meta-analyses consistently demonstrate that ASPs reduce antibiotic consumption by 20–40%, reduce CDI rates by 15–50%, reduce healthcare-associated infections by multidrug-resistant organisms, and reduce antimicrobial acquisition costs without adversely affecting patient mortality or length of hospital stay. [16] Core ASP interventions include: prospective audit and feedback (pharmacist or infectious disease physician review of antibiotic prescriptions with prescriber feedback), formulary restriction and pre-authorization for restricted antibiotics, IV-to-oral conversion protocols, duration-of-therapy optimization using pharmacodynamic principles, and de-escalation of empiric broad-spectrum therapy upon availability of culture and sensitivity data.

6.2 The Community-Level ASP Imperative

While hospital-based ASPs are well-established, the majority of antibiotic prescribing in the United States occurs in the outpatient (community) setting — primarily primary care physician offices, urgent care centers, and emergency departments. Extending stewardship principles to the community level is therefore essential. Point-of-care rapid diagnostic testing (RADT for Group A Streptococcus; rapid influenza testing; procalcitonin for bacterial vs. viral sepsis differentiation) enables evidence-based antibiotic withholding in viral illnesses. Patient education programs that reframe antibiotic expectations — countering the cultural expectation that antibiotics are appropriate for "any infection" — are a critical behavioral intervention. The availability of OTC systemic antibiotics, even if theoretically restricted to certain indications, would fundamentally undermine these community stewardship efforts by removing the prescriber as a gatekeeping clinical decision-maker.

7. Conclusion

The regulatory distinction maintained by the FDA between topical OTC antibiotics and systemic prescription antibiotic agents is not an artifact of regulatory conservatism; it is an evidence-based public health safeguard grounded in decades of pharmacological, microbiological, and epidemiological science. The data are unambiguous: unrestricted access to systemic antibiotics — whether through formal OTC availability, unregulated online sources, or informal sharing — accelerates antimicrobial resistance, selects for resistant commensals, disrupts the microbiome with wide-ranging health consequences, and perpetuates the self-diagnosis paradigm that consistently leads to antibiotic use for viral illnesses where no pharmacological benefit exists.

The CDC's estimate that 30% of ambulatory antibiotic prescriptions in the United States are already inappropriate under optimal professional supervision conditions should give pause to any proposal to further reduce clinical oversight. The AMR crisis is, fundamentally, a problem of antibiotic overuse and misuse — and every intervention that increases accessibility of systemic antibiotics without commensurate increases in diagnostic precision and prescribing oversight is an intervention that worsens the very crisis it may purport to address. The academic, public health, and medical communities in the United States must maintain unwavering advocacy for evidence-based antimicrobial stewardship principles as the definitive framework for navigating the AMR challenge.

Future research priorities should include: expanded development and validation of rapid point-of-care diagnostics to facilitate real-time bacterial vs. viral differentiation in community settings; longitudinal microbiome studies to quantify the long-term health consequences of antibiotic-induced dysbiosis across the life course; pharmacoeconomic analyses of ASP interventions to strengthen the health systems case for stewardship investment; and continued molecular epidemiology of resistance gene dissemination to inform evidence-based regulatory and antimicrobial use policy at the federal level.

8. References

• [1] Centers for Disease Control and Prevention. (2023). Antibiotic Resistance Threats in the United States, 2023 Update. Atlanta, GA: US Department of Health and Human Services. Retrieved from https://www.cdc.gov/antibiotic-use/
• [2] Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 353(b). (1951, as amended). Prescription Drug Amendments, Durham-Humphrey Amendment. United States Congress.
• [3] US Food and Drug Administration. (2022). OTC Drug Monograph: First Aid Antibiotic Ointments. 21 CFR Part 333. Silver Spring, MD: FDA.
• [4] Van Boeckel, T.P., Gandra, S., Ashok, A., Caudron, Q., Grenfell, B.T., Levin, S.A., & Laxminarayan, R. (2014). Global antibiotic consumption 2000 to 2010: An analysis of national pharmaceutical sales data. The Lancet Infectious Diseases, 14(8), 742–750. doi:10.1016/S1473-3099(14)70780-7
• [5] Andersson, D.I., & Hughes, D. (2011). Persistence of antibiotic resistance in bacterial populations. FEMS Microbiology Reviews, 35(5), 901–911. doi:10.1111/j.1574-6976.2011.00289.x
• [6] Drlica, K., & Zhao, X. (2007). Mutant selection window hypothesis updated. Clinical Infectious Diseases, 44(5), 681–688. doi:10.1086/511642
• [7] Sommer, M.O.A., Dantas, G., & Church, G.M. (2009). Functional characterization of the antibiotic resistance reservoir in the human microflora. Science, 325(5944), 1128–1131. doi:10.1126/science.1176950
• [8] Panda, S., El khader, I., Casellas, F., et al. (2014). Short-term effect of antibiotics on human gut microbiota. PLOS ONE, 9(4), e95476. doi:10.1371/journal.pone.0095476
• [9] Harris, A.M., Hicks, L.A., & Qaseem, A. (2016). Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention. Annals of Internal Medicine, 164(6), 425–434.
• [10] Linder, J.A., & Stauffer, W.M. (2012). Duration of antibiotic therapy for acute respiratory infections. JAMA Internal Medicine, 172(17), 1326–1327.
• [11] Sender, R., Fuchs, S., & Milo, R. (2016). Revised estimates for the number of human and bacteria cells in the body. Cell, 164(3), 337–340. doi:10.1016/j.cell.2016.01.013
• [12] Jernberg, C., Löfmark, S., Edlund, C., & Jansson, J.K. (2010). Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology, 156(Pt 11), 3216–3223. doi:10.1099/mic.0.040618-0
• [13] McDonald, L.C., Gerding, D.N., Johnson, S., et al. (2018). Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases, 66(7), e1–e48.
• [14] Mårild, K., Ye, W., Lebwohl, B., Green, P.H., Blaser, M.J., Card, T., & Ludvigsson, J.F. (2013). Antibiotic exposure and the development of celiac disease: A nationwide case–control study. BMC Gastroenterology, 13, 109. doi:10.1186/1471-230X-13-109
• [15] Barlam, T.F., Cosgrove, S.E., Abbo, L.M., et al. (2016). Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clinical Infectious Diseases, 62(10), e51–e77. doi:10.1093/cid/ciw118
• [16] Schuts, E.C., Hulscher, M.E.J.L., Mouton, J.W., et al. (2016). Current evidence on hospital antimicrobial stewardship objectives: A systematic review and meta-analysis. The Lancet Infectious Diseases, 16(7), 847–856. doi:10.1016/S1473-3099(16)00065-7